Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q2

4564.TEDINET S100S8MF
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥356m2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥515m2022-04-01 → 2022-09-30Cons.Net sales
Operating income−¥695m2023-04-01 → 2023-09-30Cons.Operating income
Operating income−¥618m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income−¥708m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥1.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥644m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥709m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax−¥613m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥711m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.1bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥614m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥711m2023-04-01 → 2023-09-30Cons.Profit loss
Net income−¥614m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥1.2bnat 2023-09-30Cons.Assets
Total assets¥1.5bnat 2023-03-31Cons.Assets
Total assets¥1.7bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥233mat 2023-09-30Cons.Liabilities
Total liabilities¥656mat 2023-03-31Cons.Liabilities
Net assets / equity¥935mat 2023-09-30Cons.Net assets
Net assets / equity¥855mat 2023-03-31Cons.Net assets
Net assets / equity¥1.3bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥881mat 2023-09-30Cons.Cash and deposits
Cash and deposits¥1.1bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥881mat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥1.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.8bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥880m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥795m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥517m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥34m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥20m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥677m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥96m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-3.422023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.452023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.812022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.192022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.742022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio73.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio51.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio76.3%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥183m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥109m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥537,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥387,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥149,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥403m
—segment totalrevenue2023-04-01 → 2023-09-30¥357m
—segment totalrevenue external2023-04-01 → 2023-09-30¥356m
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥149,000
—segment totalsegment profit2023-04-01 → 2023-09-30−¥512m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥188m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥48m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥111,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-09-30−¥382m
—segment totalrevenue2022-04-01 → 2022-09-30¥515m
—segment totalrevenue external2022-04-01 → 2022-09-30¥515m
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥111,000
—segment totalsegment profit2022-04-01 → 2022-09-30−¥430m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 421
ItemContextValueUnit
Capital surplusPrior1YearInstant24793617000JPY
Capital surplusCurrentQuarterInstant25188317000JPY
Retained earningsPrior1YearInstant-24804823000JPY
Retained earningsCurrentQuarterInstant-25515486000JPY
Shareholders equityPrior1YearInstant777908000JPY
Shareholders equityCurrentQuarterInstant856645000JPY
Subscription rights to sharesPrior1YearInstant77260000JPY
Subscription rights to sharesCurrentQuarterInstant78350000JPY
Net assetsPrior1YearInstant855169000JPY
Net assetsCurrentQuarterInstant934995000JPY
Liabilities and net assetsPrior1YearInstant1511438000JPY
Liabilities and net assetsCurrentQuarterInstant1167733000JPY
Business revenuePrior1YTDDuration514566000JPY
Business revenueCurrentYTDDuration356452000JPY
Cost of salesPrior1YTDDuration511296000JPY
Cost of salesCurrentYTDDuration444847000JPY
Research and development expenses sgaPrior1YTDDuration404229000JPY
Research and development expenses sgaCurrentYTDDuration405761000JPY
Selling general and administrative expensesPrior1YTDDuration217118000JPY
Selling general and administrative expensesCurrentYTDDuration200603000JPY
Business expensesPrior1YTDDuration1132644000JPY
Business expensesCurrentYTDDuration1051212000JPY
Operating incomePrior1YTDDuration-618078000JPY
Operating incomeCurrentYTDDuration-694759000JPY
Interest on refund noiPrior1YTDDuration87000JPY
Interest on refund noiCurrentYTDDuration19000JPY
Other noiPrior1YTDDuration－JPY
Other noiCurrentYTDDuration6000JPY
Non operating incomePrior1YTDDuration87000JPY
Non operating incomeCurrentYTDDuration26000JPY
Stock issuance cost noePrior1YTDDuration－JPY
Stock issuance cost noeCurrentYTDDuration8479000JPY
Foreign exchange losses noePrior1YTDDuration9421000JPY
Foreign exchange losses noeCurrentYTDDuration4972000JPY
Relocation expenses noePrior1YTDDuration16161000JPY
Relocation expenses noeCurrentYTDDuration－JPY
Non operating expensesPrior1YTDDuration25583000JPY
Non operating expensesCurrentYTDDuration13452000JPY
Ordinary incomePrior1YTDDuration-643574000JPY
Ordinary incomeCurrentYTDDuration-708185000JPY
Gain on reversal of subscription rights to shares eiPrior1YTDDuration37755000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration1375000JPY
Extraordinary incomePrior1YTDDuration37755000JPY
Extraordinary incomeCurrentYTDDuration1375000JPY
Impairment loss elPrior1YTDDuration6941000JPY
Impairment loss elCurrentYTDDuration2627000JPY
Extraordinary lossPrior1YTDDuration6941000JPY
Extraordinary lossCurrentYTDDuration2627000JPY
Income before income taxesPrior1YTDDuration-612760000JPY
Income before income taxesCurrentYTDDuration-709438000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass